Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision
This article was originally published in The Pink Sheet Daily
Executive Summary
California Democrat drops data exclusivity to 12 years, plus six months for pediatric studies, and removes requirement for FDA guidance before approval.